KRAS and neoplasm: Collectively, these data suggest that multiple tumor clones with distinct mitogenic drivers (either RET or KRAS) may co-exist at baseline, each shedding into circulation at different rates, ultimately leading to either short duration of at-best mixed response or primary resistance (Fig. 2e).